Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Johannes, Ruef"'
Autor:
Marc Bosiers, Thomas Jahnke, Johannes Ruef, Stefan Müller-Hülsbeck, Renate Koppensteiner, Herman Schroë, Giovanni Torsello, Dierk Scheinert, Hans-Martin Gissler, Patrick Peeters, Johannes Lammer, Klaus Mathias, Frank Vermassen, Kim Daenens
Publikováno v:
Journal of Endovascular Therapy. 16:261-269
To evaluate the long-term efficacy and integrity of the PROTEGE EverFlex stent in superficial femoral artery (SFA) lesions in symptomatic patients with peripheral artery disease (PAD).A prospective, multicenter, nonrandomized study enrolled 151 subje
Publikováno v:
Catheterization and Cardiovascular Interventions. 71:333-339
Background: In selected patient cohorts the polymer-free rapamycin-eluting YUKON stent (A) has demonstrated noninferiority compared with the polymer-based paclitaxel-eluting TAXUS stent (B). To test for equivalency in unselected real-world patients w
Publikováno v:
Cardiovascular Revascularization Medicine. 8:170-174
Background Prior to the introduction of drug-eluting stents (DES), diffuse coronary in-stent restenosis (ISR) was mainly treated by brachytherapy (BT), with good short-term and mid-term results. However, there exist limited data on the long-term effe
Autor:
Johannes Ruef, Roger Kranzhöfer
Publikováno v:
Platelets. 17:163-169
Aspirin resistance (AR) is estimated to be present in 5-75% of patients and is related to increased cardiovascular mortality. However, the underlying mechanisms are mostly unknown. In the present study, AR was detected in 14 out of 55 patients (25%)
Autor:
Johannes Ruef
Publikováno v:
Medizinische Klinik. 99:65-70
Aufgrund einer Fulle von klinisch-wissenschaftlichen Daten stellen Statine ein wesentliches Standbein der primaren und sekundaren Prophylaxe ischamischer Ereignisse dar. Schon vor Bekanntwerden der Tatsache, dass Statine auch bei normalen Lipidspiege
Publikováno v:
Journal of Cardiovascular Pharmacology. 41:586-592
Platelet GPIIb/IIIa antagonists are not only used to prevent platelet aggregation, but also in combination with thrombolytic agents for the treatment of coronary thrombi. Recent data indicate a potential of abciximab alone to dissolve thrombi in vivo
Autor:
Nageswara R, Madamanchi, Zhao Y, Hu, Fengzhi, Li, Chris, Horaist, Sung-Kwon, Moon, Cam, Patterson, Marschall S, Runge, Johannes, Ruef, Pamela H, Fritz, Joann, Aaron
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1576:237-245
Activation of the human protease-activated receptor-1 (PAR-1) by thrombin leads to myriad functions essential for maintaining vascular integrity. Upregulation of PAR-1 expression is considered important in atherosclerosis, angiogenesis and tumor meta
Autor:
Silke Behrens, Helmut F. Kuecherer, Raffi Bekeredjian, Johannes Ruef, Marina Baum, Eckhard Dinjus, Eberhard Unger
Publikováno v:
Ultrasound in Medicine & Biology. 28:691-695
Contrast agents based on gas-filled microspheres share the problem of time limited opacification due to low stability of microbubbles. The aim of this study was to test if gold-bound microtubules provide backscattering that allows microtubules to be
Autor:
Andreas Straub, Johannes Ruef, Thomas K. Nordt, Christoph Bode, Raffi Bekeredjian, Ulf Bertram, Martin Moser, Karlheinz Peter, Helmut F. Kuecherer
Publikováno v:
Journal of Thrombosis and Thrombolysis. 14:197-203
Background: Due to considerably high rates of reocclusion under standard thrombolytic therapy GP IIb/IIIa inhibitors have been combined with thrombolytics to improve therapeutic outcomes. Potential reasons for arterial reocclusion may be increased pl
Autor:
Johannes Ruef, Christoph Bode, Steffen Lutzi, Wolfgang Kübler, Karlheinz Peter, Burton E. Sobel, Thomas K. Nordt, Ernst Klar
Publikováno v:
Thrombosis and Haemostasis. 86:1305-1313
SummaryHuman atherosclerotic lesions exhibit increased expression of plasminogen activator inhibitor type-1 (PAI-1) that has been implicated in atherogenesis. Although vascular smooth muscle cells are a predominant source of PAI-1 expression potentia